ESMO E-Learning: Clinical Cases in Bladder Cancer: Adherence to the ESMO Clinical Practice Guidelines
- To understand clinical strategies for diagnosis, staging, treatment, and follow-up of bladder cancer
- To understand the treatment approaches in patients with non-muscle and muscle-invasive bladder cancer
- To understand the benefit of local and systemic treatments in patients with bladder cancer
|Title||Duration||Content||CME Points||CME Test|
|Clinical Cases in Bladder Cancer: Adherence to the ESMO Clinical Practice Guidelines||20 min.||38 slides||1||Take Test|
This presentation has been developed with the aim of discussing a clinical perspective of the recently revised ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of bladder cancer. The module consists of two particular patient cases with described clinical scenario and subsequent discussion about treatment options.
Ninety per cent of bladder carcinomas are transitional cell carcinomas. Most patients present with painless hematuria, though some present with dysuria and, rarely, symptoms of metastases. Most of the diagnosed cases of muscle-invasive bladder cancer (80-90%) present as primary invasive bladder cancer. Up to 15% of patients, however, have a history of non-muscle invasive bladder cancer.
This E-Learning module is composed of two clinical cases. The first one follows a clinical scenario during the progressive course of initial early stage disease. The second case discusses the neo- and adjuvant treatment decisions in a patient with stage III disease, and subsequent follow-up strategy.
Aiming to enhance experience with the ESMO Clinical Practice Guidelines material, we strongly recommend oncology professionals to refer to the full version of the guidelines text available in the Supplement of the Annals of Oncology, as well as Clinical Practice Guidelines section.
The author has reported no conflicts of interest.